Combination therapy with a T-cell engager and chemotherapy for pancreatic cancer
Official title: Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment
Funded at Oncotab, INC · NIH-11404568 · Data updated 2026-11-12
A new treatment approach combines a T-cell engaging antibody with standard chemotherapy to help treat pancreatic cancer, aiming to slow tumor growth and improve outcomes.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncotab, INC NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,130,587 |
| NIH project number | 1R44CA306447-01A1 |
| Project ID | NIH-11404568 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable at this stage (preclinical work); future trials would enroll patients with pancreatic cancer.
✕Less likely to help
No direct patient benefit until later clinical trials are conducted.
What this research studies
This project builds on earlier work to create a bispecific antibody that directs T cells to pancreatic tumors. It will test MUCD3 in combination with Abraxane and gemcitabine in preclinical models to see if the combo overcomes chemotherapy resistance and reduces harmful immune reactions. The work focuses on key preclinical steps, including stability, pharmacokinetics, and safety data to prepare for first-in-human trials. If successful, these studies could pave the way for a novel therapy option for patients with pancreatic cancer who have limited current choices.
Why it matters
Potential benefit: If successful, the research could lead to a new treatment option that slows pancreatic cancer and potentially improves survival.
How similar studies have gone: Previous work showed that MUCD3 slows tumor growth and that combining with chemotherapy may enhance effect while reducing cytokine release.
Where this research is happening
-
Oncotab, INC
Charlotte, United States Active
Researchers
- Principal investigator: Puri, Rahul — Oncotab, INC
- Study coordinator: Puri, Rahul
Related research
Other NIH-funded projects on the same topics.
-
Tumor-targeted delivery of radio/chemotherapy for pancreatic cancer
A new treatment approach combines a targeted drug delivery system with a radioactive payload to attack pancreatic cancer cells that have mutant KRAS.
-
MRI-guided chemotherapy for borderline-resectable pancreatic cancer
This project uses special MRI scans to help pick the best pre-surgery chemotherapy for people whose pancreatic tumor is touching nearby vessels but might be removable after treatment.
-
A targeted therapy plan using endoscopic heat treatment plus chemotherapy for pancreatic cancer
A patient-focused plan tests using a special endoscopic heat treatment together with chemotherapy to treat pancreatic cancer.
-
Combining Chemotherapy with Targeted Ablation for Pancreatic Cancer
This research is testing a new way to treat pancreatic cancer by combining standard chemotherapy with a targeted heat treatment called radiofrequency ablation.
-
Understanding how cancer metabolism affects chemotherapy resistance in pancreatic cancer
This study is looking into why pancreatic cancer doesn't respond well to regular chemotherapy and hopes to find new ways to make these treatments work better for patients like you.
-
Combining chemotherapy with a new treatment method for pancreatic cancer
This study is looking at how well combining regular chemotherapy with a special treatment called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) works for people with pancreatic cancer, hoping to boost their immune response and improve their chances of recovery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.